Syed Ibrahim Bukhari: From Conventional Therapy to Gene-Based Approaches in Hemophilia Care
Syed Ibrahim Bukhari, Clinical Fellow at The Hospital for Sick Children, shared a post on LinkedIn:
“In honor of World Hemophilia Day 2025, I had the privilege of presenting on ‘Hemophilia Management: Current Standards and Emerging Frontiers’ at the National Institute of Child Health (NICH) in Karachi.
The session focused on the critical importance of specialized care for pediatric patients and the evolving landscape of treatment.
Key Highlights from the Presentation:
The Core Challenge: Hemophilia A and B are X-linked recessive disorders characterized by deficiencies in clotting factors VIII and IX, respectively, leading to prolonged bleeding and potential joint damage.
Diagnosis and Severity: We discussed the importance of classifying severity based on factor levels—Severe (<1 percent), Moderate (1-5 percent), and Mild (5-40 percent)—to tailor treatment effectively.
Management Pillars: The talk emphasized the ‘P.R.I.C.E’ protocol for acute bleeds (Protection, Rest, Ice, Compression, Elevation) alongside prompt factor replacement therapy.
Prophylaxis versus Episodic Care: A major focus was the shift toward prophylaxis (regular treatment to prevent bleeds) as the gold standard for preventing chronic hemophilic arthropathy and improving quality of life.
Inhibitors and Complications: We addressed the challenge of inhibitors, where the body’s immune system reacts against replacement factors, necessitating advanced bypass agents or immune tolerance induction.
Future Frontiers: I shared insights into the potential of gene therapy and non-factor replacement therapies, like Emicizumab, which are revolutionizing how we approach long-term care.
Thank you to the team at NICH for organizing this event and for their unwavering commitment to our young patients in Karachi.
Together, we can strive for a future where ‘Access for All’ becomes a reality.”

See more in the gallery.
Stay updated with Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders